楼主: wyd147258
711 0

[其他] 抗体药物质控资料 [推广有奖]

  • 0关注
  • 0粉丝

学前班

40%

还不是VIP/贵宾

-

威望
0
论坛币
0 个
通用积分
0
学术水平
0 点
热心指数
0 点
信用等级
0 点
经验
20 点
帖子
1
精华
0
在线时间
0 小时
注册时间
2024-8-19
最后登录
2024-8-19

楼主
wyd147258 发表于 2024-8-19 23:29:17 |AI写论文

+2 论坛币
k人 参与回答

经管之家送您一份

应届毕业生专属福利!

求职就业群
赵安豆老师微信:zhaoandou666

经管之家联合CDA

送您一个全额奖学金名额~ !

感谢您参与论坛问题回答

经管之家送您两个论坛币!

+2 论坛币
A "sequence variant" is a surrogate term covering any unintentional amino acid substitutions, omissions, or insertions during protein biosynthesis. Production of biotherapeutic proteins by living organisms is governed by biological processes responsible for protein production, including DNA replication, RNA transcription, and protein translation steps. Each of the biosynthesis steps has finite fidelity, with error rates ranging from 10-9 per base pair for DNA replication to 10-4 to 10-5 per codon for protein translation. The occurrence of sequence variants contributes to heterogeneity of recombinant protein therapeutics. Establishing a sequence variant profile of a biotherapeutic product is essential in providing proof of its structure, its manufacturing consistency, and the stability of the producing cell line. DNA mutations can arise during generation of stable producing cell lines and be amplified by selection pressures used to establish high-producing clones.
二维码

扫码加我 拉你入群

请注明:姓名-公司-职位

以便审核进群资格,未注明则拒绝

关键词:Therapeutics substitution establishing Translation Replication

您需要登录后才可以回帖 登录 | 我要注册

本版微信群
扫码
拉您进交流群
GMT+8, 2026-2-2 01:12